Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics |
PAR-23-280 (R21 Clinical Trial Not Allowed) |
R21 |
Clinical Trial Not Allowed |
01/08/2027 |
Edward Sauter, M.D., Ph.D. |
Notice of Special Interest (NOSI): Targeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases |
NOT-DA-22-048 |
|
|
01/08/2026 |
Sharon Ross, Ph.D., M.P.H. |
Notice of Special Interest (NOSI): Mechanisms Driving Obesity and Prostate Cancer Risk |
NOT-CA-23-089 |
|
|
09/08/2024 |
Edward Sauter, M.D., Ph.D. |
Assay Validation of High Quality Markers for Clinical Studies in Cancer |
PAR-23-313 (UH2/UH3 Clinical Trial Not Allowed) |
UH2, UH3 |
Clinical Trial Not Allowed |
10/15/2026 |
Sudhir Srivastava, Ph.D., M.P.H. |
Assay Validation of High Quality Markers for Clinical Studies in Cancer |
PAR-23-314 (UH3 Clinical Trials Not Allowed) |
UH3 |
|
10/15/2026 |
Sudhir Srivastava, Ph.D., M.P.H. |
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers |
PAR-23-286 (K99/R00 - Independent Clinical Trial Not Allowed) |
R00, K99 |
Clinical Trial Not Allowed |
10/15/2026 |
Jessica Faupel-Badger, Ph.D., M.P.H. |
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers |
PAR-23-287 (K99/R00 - Independent Clinical Trial Required) |
R00, K99 |
Clinical Trial Required |
10/15/2026 |
Jessica Faupel-Badger, Ph.D., M.P.H. |
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers |
PAR-23-288 (K99/R00 - Independent Basic Experimental Studies with Humans Required) |
R00, K99 |
|
10/15/2026 |
Jessica Faupel-Badger, Ph.D., M.P.H. |
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research |
RFA-CA-24-009 (R33 Clinical Trial Not Allowed) |
R33 |
Clinical Trial Not Allowed |
10/02/2024 |
Guillermo Marquez, Ph.D. |
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research |
RFA-CA-24-008 (R61 Clinical Trial Not Allowed) |
R61 |
Clinical Trial Not Allowed |
10/02/2024 |
Guillermo Marquez, Ph.D. |